1. Home
  2. YHGJ vs MRKR Comparison

YHGJ vs MRKR Comparison

Compare YHGJ & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunhong Green CTI Ltd.

YHGJ

Yunhong Green CTI Ltd.

N/A

Current Price

$3.17

Market Cap

11.2M

Sector

Industrials

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

N/A

Current Price

$1.41

Market Cap

23.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YHGJ
MRKR
Founded
1975
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
23.0M
IPO Year
2006
2010

Fundamental Metrics

Financial Performance
Metric
YHGJ
MRKR
Price
$3.17
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$11.25
AVG Volume (30 Days)
2.6K
145.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,953,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.84
N/A
52 Week Low
$0.47
$0.81
52 Week High
$10.29
$4.07

Technical Indicators

Market Signals
Indicator
YHGJ
MRKR
Relative Strength Index (RSI) 52.01 47.67
Support Level $0.67 $1.36
Resistance Level $3.98 $1.88
Average True Range (ATR) 0.24 0.12
MACD 0.06 0.00
Stochastic Oscillator 72.02 43.24

Price Performance

Historical Comparison
YHGJ
MRKR

About YHGJ Yunhong Green CTI Ltd.

Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: